14,025 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Purchased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. acquired a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 14,025 shares of the company’s stock, valued at approximately $1,046,000.

Several other institutional investors have also modified their holdings of the stock. Bank of America Corp DE boosted its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% in the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares during the period. Rubric Capital Management LP increased its position in shares of Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after purchasing an additional 421,347 shares during the last quarter. Janus Henderson Group PLC increased its position in shares of Kiniksa Pharmaceuticals International by 213.5% during the 1st quarter. Janus Henderson Group PLC now owns 481,023 shares of the company’s stock valued at $23,197,000 after purchasing an additional 327,595 shares during the last quarter. Spruce Street Capital LP raised its holdings in Kiniksa Pharmaceuticals International by 75.0% during the 1st quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after buying an additional 326,081 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in Kiniksa Pharmaceuticals International by 18.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after buying an additional 128,417 shares during the period. 53.95% of the stock is owned by institutional investors.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, Director G. Bradley Cole sold 3,673 shares of the firm’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at approximately $950,450.96. This trade represents a 23.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Michael Megna sold 4,600 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the transaction, the chief accounting officer owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 51.98% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on KNSA shares. Canaccord Genuity Group raised their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wedbush boosted their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the company an “overweight” rating in a research report on Wednesday, July 29th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Finally, The Goldman Sachs Group raised their target price on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Eight investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and an average target price of $93.14.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ KNSA opened at $72.98 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $35.20 and a 1 year high of $84.06. The firm has a 50-day simple moving average of $78.03 and a two-hundred day simple moving average of $59.00. The company has a market cap of $5.69 billion, a P/E ratio of 75.24 and a beta of 0.04.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting analysts’ consensus estimates of $0.30. The firm had revenue of $243.60 million for the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. As a group, equities research analysts expect that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current year.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.